PHILADELPHIA CREAM, November 3, 2023 /PRNewswire/ — Verismo Therapeutica clinical-stage CAR-T company developing novel KIR-CAR platform technology, announced today that it will present at the upcoming Society for Immunotherapy of Cancer 38 Meeting.th Annual Meeting (SITC 2023), which will be held in San Diego and virtually November 1-5, 2023.
Presentation Details
Title: Preclinical Evaluation of the Potency of SynKIR-110, a Mesothelin-Specific KIR-CAR T Cell Therapy for Mesothelioma
Abstract number: 321
Date and time: Friday November 3rd: 12:00-1:30 p.m. And 5:10 p.m.-6:40 p.m.
Presenting authors: Dr. Jun XuPhD and Dr. Laura Johnsondoctorate
Description: We conducted in vivo efficacy studies to evaluate the dose impact of engineered T cells of the first mesothelin (MSLN)-specific KIR-CAR T cell therapy (SynKIRTM-110) in a NSG mouse xenograft model of human mesothelioma. Our data demonstrate for the first time that the antitumor efficacy of SynKIRTM-110 is dose-dependent with greater potency compared to MSLN-41BBz CAR T cells previously evaluated in the clinic. This enhanced power of SynKIRTM-110 was observed at both the primary tumor site and metastatic sites as demonstrated by histopathological analysis. This increased potency had no impact on serum markers of toxicity, which remained the same regardless of CAR/KIR-CAR treatments. These data support the continued clinical development of SynKIRTM-110 in patients with advanced solid tumors. SynKIRTM-110 is currently in a Phase I STAR-101 clinical trial (NCT05568680).
About the KIR-CAR platform
The KIR-CAR platform is a dual-chain CAR T cell therapy and has been shown in preclinical animal models to be able to maintain anti-tumor T cell activity even in challenging solid tumor environments. DAP12 acts as a novel co-stimulatory molecule for T cells by utilizing additional T cell stimulatory pathways, thereby maintaining chimeric receptor expression and enhancing functional persistence of KIR-CAR T cells. This continued T cell function and persistence may lead to continued regression of solid tumors in preclinical models, including those resistant to traditional CAR T cell therapies. The KIR-CAR platform is being studied in combination with other emerging technologies.
About Verismo Therapeutics
Verismo Therapeutics is a pioneer in dual-chain KIR-CAR technology, with its lead asset SynKIR™-110 undergoing the first-in-human clinical trial. Verismo is the only company developing the KIR-CAR platform, a modified NK-like receptor designed to improve persistence and efficacy against aggressive solid tumors. The KIR-CAR platform technology was developed specifically for advanced solid tumors, an area of significant unmet medical need. For more information visit: www.verismotherapeutics.com
Media Contact:
Gene Kim
Verismo Therapeutic
PR@verismotherapeutics.com
215-989-4225
Jennifer Moritz
Zer0 to 5ive
jmoritz@0to5.com
917-748-4006
SOURCE Verismo Therapeutics
